Novartis

Latest stories

1h
FOX Business
3 Biotech Stocks to Buy on Sale Right Nowstrategy has borne fruit for the biotech. Licensing deals with larger partners
3 Biotech Stocks to Buy on Sale Right Now
FOX Business / Posted an hour ago
strategy has borne fruit for the biotech. Licensing deals with larger partners led to success with Amgen's Kyprolis and Novartis' Promacta. The two drugs currently provide most of Ligand's revenue and profits. That situation seems likely to... Read more
3 related stories
1h
FOX Business
3 Biotech Stocks to Buy on Sale Right Nowstrategy has borne fruit for the biotech. Licensing deals with larger partners
3 Biotech Stocks to Buy on Sale Right Now
FOX Business / Posted an hour ago
strategy has borne fruit for the biotech. Licensing deals with larger partners led to success with Amgen's Kyprolis and Novartis' Promacta. The two drugs currently provide most of Ligand's revenue and profits. That situation seems likely to... Read more
3 related stories
3h
MedCity News
What will separate the winners and the losers in the immuno-oncology R&D race?in the biopharma arena: The Big Five: Those with big I/O checkpoint and cell t
What will separate the winners and the losers in the immuno-oncology R&D race?
MedCity News / Posted 3 hours ago
in the biopharma arena: The Big Five: Those with big I/O checkpoint and cell therapy positions (BMS, Merck, Roche, AZ, and Novartis) are obviously focused on solidifying their “foundational” positions in the space, and in privileged spots in the... Read more
7h
News-Medical-Net
Global survey reveals 84% of psoriasis patients suffer discrimination, humiliationNovartis today released new results from the largest global survey to date of p
Global survey reveals 84% of psoriasis patients suffer discrimination, humiliation
News-Medical-Net / Posted 7 hours ago
Novartis today released new results from the largest global survey to date of people with psoriasis. Findings reveal 84% of people with moderate-to-severe psoriasis suffer discrimination and humiliation, with many being stared at in public (40%) as a... Read more
10h
Morningstar
5 Wide-Moat Stocks Now Selling at a Discountyears," Gorham says. "We expect that figure to remain fairly flat during the ne
5 Wide-Moat Stocks Now Selling at a Discount
Morningstar / Posted 10 hours ago
years," Gorham says. "We expect that figure to remain fairly flat during the next five years." Fair value estimate: $89 Novartis derives its strength from a diversified operating platform that includes branded pharmaceuticals, generics, eye-care... Read more
19h
The Signal
US stocks rebound as anxiety over British vote eases500 index. The stock added $2.50 to $16.19. Xencor vaulted 32.1 percent after
US stocks rebound as anxiety over British vote eases
The Signal / Posted 19 hours ago
500 index. The stock added $2.50 to $16.19. Xencor vaulted 32.1 percent after the drugmaker announced a partnership with Novartis to develop two cancer drugs. The stock rose $4.02 to $16.56. Several energy companies also notched... Read more
210 related stories
21h
TribLIVE
Energy, bank stocks lead rebound as anxiety over British vote eases500 index. The stock added $2.50 to $16.19. Xencor vaulted 32.1 percent after
Energy, bank stocks lead rebound as anxiety over British vote eases
TribLIVE / Posted 21 hours ago
500 index. The stock added $2.50 to $16.19. Xencor vaulted 32.1 percent after the drugmaker announced a partnership with Novartis to develop two cancer drugs. The stock rose $4.02 to $16.56. Several energy companies also notched... Read more
210 related stories
22h
The Middletown Press
US stocks rebound as anxiety over British vote eases500 index. The stock added $2.50 to $16.19. Xencor vaulted 32.1 percent after
US stocks rebound as anxiety over British vote eases
The Middletown Press / Posted 22 hours ago
500 index. The stock added $2.50 to $16.19. Xencor vaulted 32.1 percent after the drugmaker announced a partnership with Novartis to develop two cancer drugs. The stock rose $4.02 to $16.56. Several energy companies also notched... Read more
210 related stories
22h
Los Angeles Times
Xencor signs cancer-drug deal with Novartis; its stock surges 32%of Los Angeles-area biotech firm Xencor Inc. soared Tuesday by 32% after the co
Xencor signs cancer-drug deal with Novartis; its stock surges 32%
Los Angeles Times / Posted 22 hours ago
of Los Angeles-area biotech firm Xencor Inc. soared Tuesday by 32% after the company announced a deal with Swiss drug giant Novartis. Under the agreement, Novartis will pay Xencor $150 million now and potentially much more in the future as the... Read more
2 related stories
23h
Investopedia
Pfizer to Build $350M Biotech Center in China (PFE)rest of Asia. (For related reading, see: Pfizer Stock Rises Despite Price Targe
Pfizer to Build $350M Biotech Center in China (PFE)
Investopedia / Posted 23 hours ago
rest of Asia. (For related reading, see: Pfizer Stock Rises Despite Price Target Cut.) The setup by Pfizer is not new, as Novartis (NVS) was the first one to open a $1 billion research center in China for research towards lung, liver and gastric... Read more
4 related stories
1d
FOX Business
Why Xencor Inc's Shares Are Skyrocketing Todayof 3:20 p.m. EDT after news broke that the company has signed a lucrative colla
Why Xencor Inc's Shares Are Skyrocketing Today
FOX Business / Posted yesterday
of 3:20 p.m. EDT after news broke that the company has signed a lucrative collaboration agreement with Swiss pharma giant Novartis . So what: Novartis has agreed to pay a $150 million upfront fee to get its hands on two of Xencor's pipeline... Read more
2 related stories
1d
FOX Business
Why Xencor Inc's Shares Are Skyrocketing Todayof 3:20 p.m. EDT after news broke that the company has signed a lucrative colla
Why Xencor Inc's Shares Are Skyrocketing Today
FOX Business / Posted yesterday
of 3:20 p.m. EDT after news broke that the company has signed a lucrative collaboration agreement with Swiss pharma giant Novartis . So what: Novartis has agreed to pay a $150 million upfront fee to get its hands on two of Xencor's pipeline... Read more
2 related stories
1d
Orange County Register
U.S. stocks rebound as anxiety over British vote eases500 index. The stock added $2.57 to $16.26. Xencor vaulted 34.9 percent after
U.S. stocks rebound as anxiety over British vote eases
Orange County Register / Posted yesterday
500 index. The stock added $2.57 to $16.26. Xencor vaulted 34.9 percent after the drugmaker announced a partnership with Novartis to develop two cancer drugs. The stock rose $4.36 to $16.90. Several energy companies also notched... Read more
210 related stories
1d
Island Packet
Hess rises and ReachLocal skyrockets; Regulus, Dow fallfor $4.60 per share, or $138.4 million. Xencor Inc., up $4.02 to $16.56 The d
Hess rises and ReachLocal skyrockets; Regulus, Dow fall
Island Packet / Posted yesterday
for $4.60 per share, or $138.4 million. Xencor Inc., up $4.02 to $16.56 The drug developer announced a partnership with Novartis to develop potential cancer drugs and will get $150 million up front. Regulus Therapeutics Inc., down $2.47 to... Read more
1d
KFVS 12 Cape Girardeau
US stocks rebound as anxiety over British vote eases500 index. The stock added $2.57 to $16.26. Xencor vaulted 34.9 percent after
US stocks rebound as anxiety over British vote eases
KFVS 12 Cape Girardeau / Posted yesterday
500 index. The stock added $2.57 to $16.26. Xencor vaulted 34.9 percent after the drugmaker announced a partnership with Novartis to develop two cancer drugs. The stock rose $4.36 to $16.90. Several energy companies also notched... Read more
210 related stories
1d
The Mercury News
U.S. stocks rebound as anxiety over British vote eases500 index. The stock added $1.95 to $15.64. Xencor vaulted 35.6 percent after
U.S. stocks rebound as anxiety over British vote eases
The Mercury News / Posted yesterday
500 index. The stock added $1.95 to $15.64. Xencor vaulted 35.6 percent after the drugmaker announced a partnership with Novartis to develop two cancer drugs. The stock rose $4.47 to $17.03. Several energy companies also notched... Read more
210 related stories
1d
KWWL Iowa
US stocks rebound as anxiety over British vote eases500 index. The stock added $2.57 to $16.26. Xencor vaulted 34.9 percent after
US stocks rebound as anxiety over British vote eases
KWWL Iowa / Posted yesterday
500 index. The stock added $2.57 to $16.26. Xencor vaulted 34.9 percent after the drugmaker announced a partnership with Novartis to develop two cancer drugs. The stock rose $4.36 to $16.90. Several energy companies also notched... Read more
210 related stories
1d
Silicon Valley
U.S. stocks rebound as anxiety over British vote eases500 index. The stock added $1.95 to $15.64. Xencor vaulted 35.6 percent after
U.S. stocks rebound as anxiety over British vote eases
Silicon Valley / Posted yesterday
500 index. The stock added $1.95 to $15.64. Xencor vaulted 35.6 percent after the drugmaker announced a partnership with Novartis to develop two cancer drugs. The stock rose $4.47 to $17.03. Several energy companies also notched... Read more
210 related stories
1d
Staten Island Advance
U.S. stocks rebound as anxiety over British vote eases500 index. The stock added $1.95 to $15.64. Xencor vaulted 35.6 percent after
U.S. stocks rebound as anxiety over British vote eases
Staten Island Advance / Posted yesterday
500 index. The stock added $1.95 to $15.64. Xencor vaulted 35.6 percent after the drugmaker announced a partnership with Novartis to develop two cancer drugs. The stock rose $4.47 to $17.03. Several energy companies also notched... Read more
210 related stories
1d
FOX Business
Forget Stem Cell Stocks: Here Are 3 Clinical-Stage Biotechs to Buy Insteaddegeneration (AMD). Ophthotech is currently studying Fovista alongside a handfu
Forget Stem Cell Stocks: Here Are 3 Clinical-Stage Biotechs to Buy Instead
FOX Business / Posted yesterday
degeneration (AMD). Ophthotech is currently studying Fovista alongside a handful of blockbuster eye disease drugs like Novartis' Lucentis and Regeneron Pharmaceuticals' Eylea. Image source: Pixarc on Pixabay. Mid-stage clinical trial results... Read more
1d
FOX Business
Forget Stem Cell Stocks: Here Are 3 Clinical-Stage Biotechs to Buy Insteaddegeneration (AMD). Ophthotech is currently studying Fovista alongside a handfu
Forget Stem Cell Stocks: Here Are 3 Clinical-Stage Biotechs to Buy Instead
FOX Business / Posted yesterday
degeneration (AMD). Ophthotech is currently studying Fovista alongside a handful of blockbuster eye disease drugs like Novartis' Lucentis and Regeneron Pharmaceuticals' Eylea. Image source: Pixarc on Pixabay. Mid-stage clinical trial results... Read more
1d
MedCity News
Medtronic buys HeartWare for $1.1B, SCOTUS denies Sequenom appeal on patent for DNA testFDA discovered serious irregularities in a study of a mind-altering, experiment
Medtronic buys HeartWare for $1.1B, SCOTUS denies Sequenom appeal on patent for DNA test
MedCity News / Posted yesterday
FDA discovered serious irregularities in a study of a mind-altering, experimental drug. — The New York Times In deals with Novartis and Eli Lilly, Harvard Pilgrim Health Care has become the latest insurer to tie drug reimbursements to patient... Read more
1d
iol.co.za
Pfizer invests $350m in China facilitycountry for drugmakers from Pfizer to the UK’s GlaxoSmithKline and AstraZeneca
Pfizer invests $350m in China facility
iol.co.za / Posted yesterday
country for drugmakers from Pfizer to the UK’s GlaxoSmithKline and AstraZeneca last year. Still, multinationals including Novartis AG continue to invest in China, where a rising middle class is boosting spending on health care. “China is one of... Read more
1d
Swissinfo
Pfizer Bolsters China Presence With $350 Million Biotech Plantfor drugmakers from Pfizer to the U.K.’s GlaxoSmithKline Plc and AstraZeneca Pl
Pfizer Bolsters China Presence With $350 Million Biotech Plant
Swissinfo / Posted yesterday
for drugmakers from Pfizer to the U.K.’s GlaxoSmithKline Plc and AstraZeneca Plc last year. Still, multinationals including Novartis AG continue to invest in China, where a rising middle class is boosting spending on health care. “China is one of... Read more
1d
The Economic Times
USFDA nods to Indian drugs up 84% in 1 yearof Otsuka's Abilify (aripiprazole) used for treating schizophrenia; Vigamox (mo
USFDA nods to Indian drugs up 84% in 1 year
The Economic Times / Posted yesterday
of Otsuka's Abilify (aripiprazole) used for treating schizophrenia; Vigamox (moxifloxacin), a conjunctivitis drug made by Novartis company Alcon; Zetia (ezetimibe), a drug prescribed for treating hypertension made by MSD; and anti-cancer drug... Read more
1d
dna
Look for a better deal in that buyback offerthe start of the year, sizeable companies such as Dr Reddy's, Wipro, Excel Indu
Look for a better deal in that buyback offer
dna / Posted yesterday
the start of the year, sizeable companies such as Dr Reddy's, Wipro, Excel Industries, Bharti Infratel and Bharti Airtel, Novartis, Nalco, NMDC, MOIL, Coal India, On Mobile and Sun Pharma have announced buyback offers. As per Prime Database, just... Read more
1d
Fortune
Why a Bipartisan Bill Is Pitting the Biopharma Industry Against Itselfindustry players against each other. Pointing to skyrocketing medication price
Why a Bipartisan Bill Is Pitting the Biopharma Industry Against Itself
Fortune / Posted yesterday
industry players against each other. Pointing to skyrocketing medication prices, including for old treatments like the Novartis nvs cancer drug Gleevec, Rep. Jan Schakowsky (D-Illinois), McCain, and Brown introduced the Price Relief,... Read more
2d
Boston Globe
Harvard Pilgrim adds new drugs under ‘pay-for-performance dealseffectiveness. The new pacts, set to be disclosed Monday, cover Entresto, a he
Harvard Pilgrim adds new drugs under ‘pay-for-performance deals
Boston Globe / Posted 2 days ago
effectiveness. The new pacts, set to be disclosed Monday, cover Entresto, a heart failure treatment from Swiss drug maker Novartis AG, and Trulicity, a diabetes drug from Eli Lilly and Co. Under the contracts, both will be listed as preferred... Read more
2d
FOX Business
What Is a Biosimilar?2010, there wasn't a regulatory pathway for biosimilars.The FDA granted approva
What Is a Biosimilar?
FOX Business / Posted 2 days ago
2010, there wasn't a regulatory pathway for biosimilars.The FDA granted approval to the first U.S. biosimilar, Zarxio from Novartis,on March 6, 2015, just a few weeks ahead of the ACA's fifth anniversery. Because of a mandatory six-month waiting... Read more
2d
FOX Business
What Is a Biosimilar?2010, there wasn't a regulatory pathway for biosimilars.The FDA granted approva
What Is a Biosimilar?
FOX Business / Posted 2 days ago
2010, there wasn't a regulatory pathway for biosimilars.The FDA granted approval to the first U.S. biosimilar, Zarxio from Novartis,on March 6, 2015, just a few weeks ahead of the ACA's fifth anniversery. Because of a mandatory six-month waiting... Read more
4d
FOX Business
3 Biotech Stocks to Buy in Julyof super-aggressive Kite Pharma, Inc. . Because of its recent actions, the clin
3 Biotech Stocks to Buy in July
FOX Business / Posted 4 days ago
of super-aggressive Kite Pharma, Inc. . Because of its recent actions, the clinical-stage biotech looks set to blow past Novartis AG and Juno Therapeutics in the hot race to launch the first CAR-T therapy. While we're in uncharted territory, and... Read more
4d
FOX Business
3 Biotech Stocks to Buy in Julyof super-aggressive Kite Pharma, Inc. . Because of its recent actions, the clin
3 Biotech Stocks to Buy in July
FOX Business / Posted 4 days ago
of super-aggressive Kite Pharma, Inc. . Because of its recent actions, the clinical-stage biotech looks set to blow past Novartis AG and Juno Therapeutics in the hot race to launch the first CAR-T therapy. While we're in uncharted territory, and... Read more
4d
Daily Record
Young adults graduate from NewBridge alternative education programJohn Bickford Foundation; Community Foundation of New Jersey, Lakeland Bank, Mo
Young adults graduate from NewBridge alternative education program
Daily Record / Posted 4 days ago
John Bickford Foundation; Community Foundation of New Jersey, Lakeland Bank, Morris County Board of Chosen Freeholders, Novartis Pharmaceuticals Corporation, Provident Bank Foundation, TD Bank Charitable Foundation, Charles Emil Thenen... Read more
5d
Crain's Detroit Business
University of Michigan professor raises $27 million for new drug companyimmune system, was led by Atlas Venture of Cambridge, Mass., and Boston-based A
University of Michigan professor raises $27 million for new drug company
Crain's Detroit Business / Posted 5 days ago
immune system, was led by Atlas Venture of Cambridge, Mass., and Boston-based Abingworth, and joined by the drug company Novartis. IFM Therapeutics was incubated as part of the Atlas Venture seed program. It hopes to enhance the treatment of... Read more
5d
Business Wire
Sosei Appoints Peter Bains as CEOfor COPD which generate significant and stable revenue streams that enable furt
Sosei Appoints Peter Bains as CEO
Business Wire / Posted 5 days ago
for COPD which generate significant and stable revenue streams that enable further growth. Sosei partners include Novartis, Allergan, AstraZeneca, MedImmune, MorphoSys, Teva, and Pfizer and we are actively looking for new partnerships to... Read more
6d
Business Wire
Alnylam Pharmaceuticals Supports Greater Boston and Norton Communities with its 2nd Annual “Helping Hands” Community Service Daydemonstrated commitment to RNAi therapeutics has enabled it to form major allia
Alnylam Pharmaceuticals Supports Greater Boston and Norton Communities with its 2nd Annual “Helping Hands” Community Service Day
Business Wire / Posted 6 days ago
demonstrated commitment to RNAi therapeutics has enabled it to form major alliances with leading companies including Ionis, Novartis, Roche, Takeda, Merck, Monsanto, The Medicines Company, and Sanofi Genzyme. In addition, Alnylam holds an equity... Read more
6d
MedCity News
DOJ claims 'largest takedown ever' of $900M in Medicare frauda product of the Atlas Venture seed program, has raised a $27 Series A round fr
DOJ claims 'largest takedown ever' of $900M in Medicare fraud
MedCity News / Posted 6 days ago
a product of the Atlas Venture seed program, has raised a $27 Series A round from investors including Atlas, Abingworth and Novartis. — Business Wire Chiesi USA and parent company Chiesi Farmaceutici S.p.A. of Italy have completed the acquisition... Read more
6d
Reuters
U.S. Supreme Court weighs review of canceled patent on prenatal test40 different companies, lobbying organizations, research institutions and legal
U.S. Supreme Court weighs review of canceled patent on prenatal test
Reuters / Posted 6 days ago
40 different companies, lobbying organizations, research institutions and legal groups, including Microsoft Corp and Novartis AG, have submitted their views to the high court in 24 friend of the court briefs. All are backing Sequenom's bid to... Read more
6d
Boston Globe
At 31, she runs one of the hottest biotech companies in the countrytool could be adapted for use in agriculture, industrial biosciences, and other
At 31, she runs one of the hottest biotech companies in the country
Boston Globe / Posted 6 days ago
tool could be adapted for use in agriculture, industrial biosciences, and other fields. It has research partnerships with Novartis Institutes for Biomedical Research and DuPont, and recently finalized a deal with the animal genetics company Genus... Read more
7d
Swissinfo
Takeovers drive Swiss corporate spending spreeof Swiss cement company Holcim with French rival Lafarge to create a CHF43.5 bi
Takeovers drive Swiss corporate spending spree
Swissinfo / Posted 7 days ago
of Swiss cement company Holcim with French rival Lafarge to create a CHF43.5 billion super company. Pharmaceuticals firm Novartis was also extremely active in 2015, swapping its vaccines business with GlaxoSmithKline’s oncology unit. UNCTAD’s... Read more
7d
Investopedia
Global FDI Reaches Post-Recession Peak in 20152015 were led by a few large actions such as the Actavis-Allergan merger worth
Global FDI Reaches Post-Recession Peak in 2015
Investopedia / Posted 7 days ago
2015 were led by a few large actions such as the Actavis-Allergan merger worth $68 billion, the GlaxoSmithKline purchase of Novartis for $16 billion and Sigma-Aldrich Corp.’s acquisition by Merck KGaA for $17 billion. Without accounting for these... Read more
3 related stories
7d
Channel NewsAsia
Roche CEO 'sleeps better' as risk to drugmaker's growth recedesthese developments have boosted Schwan's optimism that Roche can more than repl
Roche CEO 'sleeps better' as risk to drugmaker's growth recedes
Channel NewsAsia / Posted 7 days ago
these developments have boosted Schwan's optimism that Roche can more than replace income lost as rivals such as Novartis and Mylan begin selling biosimilar copies of older Roche drugs in the second half of 2017. "I would have been much... Read more
7d
Business Wire
MultiModal Molecular Imaging Institute at Maastricht University Joins Waters Centers of Innovation ProgramMedicine. The event featured presentations by noted experts in imaging mass spe
MultiModal Molecular Imaging Institute at Maastricht University Joins Waters Centers of Innovation Program
Business Wire / Posted 7 days ago
Medicine. The event featured presentations by noted experts in imaging mass spectrometry including Markus Stoekli, Novartis Institutes for BioMedical Research; Prof. Klaus Dreisewerd University of Münster; Prof. Michel W. F. Nielen,... Read more
7d
Business Wire
IFM Therapeutics raccoglie 27 milioni di dollari di finanziamento di serie A guidato da Atlas Venture e Abingworthdi serie A del valore di 27 milioni di dollari guidato da Atlas Venture e Abing
IFM Therapeutics raccoglie 27 milioni di dollari di finanziamento di serie A guidato da Atlas Venture e Abingworth
Business Wire / Posted 7 days ago
di serie A del valore di 27 milioni di dollari guidato da Atlas Venture e Abingworth, con la partecipazione di Novartis. Congiuntamente ai finanziatori Jean-François Formela e Vincent Miles, soci presso Atlas e Abingworth... Read more
27 related stories
7d
Business Wire
IFM Therapeutics collecte 27 millions de dollars dans le cadre d’un tour de financement de série A dirigé par Atlas Venture et Abingworthde série A de l’ordre de 27 millions de dollars dirigé par Atlas Venture et Abi
IFM Therapeutics collecte 27 millions de dollars dans le cadre d’un tour de financement de série A dirigé par Atlas Venture et Abingworth
Business Wire / Posted 7 days ago
de série A de l’ordre de 27 millions de dollars dirigé par Atlas Venture et Abingworth, avec la participation de Novartis. En conjonction avec le financement, Jean-François Formela et Vincent Miles, partenaires à Atlas et Abingworth... Read more
83 related stories
7d
Business Wire
IFM Therapeutics realisiert unter der Führung von Atlas Venture und Abingworth Serie-Finanzierungsrunde in Höhe von 27 Millionen US-Dollarin Höhe von 27 Millionen US-Dollar, die unter der Federführung von Atlas Ventur
IFM Therapeutics realisiert unter der Führung von Atlas Venture und Abingworth Serie-Finanzierungsrunde in Höhe von 27 Millionen US-Dollar
Business Wire / Posted 7 days ago
in Höhe von 27 Millionen US-Dollar, die unter der Federführung von Atlas Venture und Abingworth, mit Beteiligung von Novartis durchgeführt wurde. Im Zusammenhang mit der Finanzierung haben sich Jean-François Formela und Vincent Miles, Partner... Read more
753 related stories
7d
Business Wire
IFM Therapeutics Raises $27 Million Series A Financing Led by Atlas Venture and Abingworthannounced the closing of a $27 million Series A financing led by Atlas Venture
IFM Therapeutics Raises $27 Million Series A Financing Led by Atlas Venture and Abingworth
Business Wire / Posted 7 days ago
announced the closing of a $27 million Series A financing led by Atlas Venture and Abingworth, with participation from Novartis. In conjunction with the funding Jean-François Formela and Vincent Miles, Partners at Atlas and Abingworth... Read more
7d
The Economic Times
MNC queue to Hyderabad grows longer; JP Morgan & IBM look for office spacecompleted the agreement for 0.2 million sq ft for 15 years period at around Rs
MNC queue to Hyderabad grows longer; JP Morgan & IBM look for office space
The Economic Times / Posted 7 days ago
completed the agreement for 0.2 million sq ft for 15 years period at around Rs 110 crore. Healthcare products giant Novartis with 1.2 million sq ft space and global audit firm Deloitte with nearly one million sq ft space are among the top... Read more
7d
Boston Globe
New genome-editing tool moves toward human trialson them, is a scientific adviser to immunotherapy companies including Celldex T
New genome-editing tool moves toward human trials
Boston Globe / Posted 7 days ago
on them, is a scientific adviser to immunotherapy companies including Celldex Therapeutics, and has been a paid speaker for Novartis, which is developing CAR T therapies. “Penn does have an infamous history in this regard,” said Dr. Lainie Ross of... Read more
10 related stories
8d
FOX Business
7 Pharmaceutical Stocks With Dividends Yielding More Than 3%are better opportunities out there with similar valuation multiples? That immed
7 Pharmaceutical Stocks With Dividends Yielding More Than 3%
FOX Business / Posted 8 days ago
are better opportunities out there with similar valuation multiples? That immediately removes AstraZeneca, GlaxoSmithKline, Novartis, and Merck & Co. from our list of stocks to consider. Image source: Getty Images. That leaves us with three... Read more
More

People in this news